PRRT therapy: interpreting published trial outcomes
A guide to the endpoints used in PRRT research and the records needed for an individual treatment discussion.
Editorial update: 3 November 2026. The study references below describe published research, not TPPL-specific outcome rates.
Which result is being described?
Tumour shrinkage, symptom control and progression-free survival answer different questions. A service should not turn one of these endpoints into a blanket cure or success promise.
NETTER-1 in context
NETTER-1 evaluated Lu-177 DOTATATE in a defined group with progressive, somatostatin-receptor-positive midgut neuroendocrine tumours. The study reported improved progression-free survival compared with its control regimen. It does not establish an identical outcome for every neuroendocrine tumour, grade or treatment line.
What the team needs
Provide pathology and grade, receptor-imaging results, previous treatments and current blood/organ-function results. The treating specialists decide whether PRRT and the published evidence fit the patient's circumstances.
Cost and planning
Ask for the proposed cycles and an itemised quote rather than inferring a total from one study. PRRT therapy and cost information.
Questions to discuss with the treating team
Does PRRT work the same way for every NET?
No. Tumour type, receptor expression, grade, previous treatments and safety assessment all affect the discussion.
Can the clinic promise the trial result for me?
No. Published trial endpoints describe groups and do not guarantee an individual result.